Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. A different strain, the Zaire ebolavirus (EBOV), is now devastating West Africa. First identified in 1976, SUDV has caused numerous Ebola outbreaks (most recently in 2012) that have killed more than 400 people in total. The findings were reported in ACS Chemical Biology.
Between 30 and 90 percent of people infected with Ebola die after experiencing symptoms of the disease that include fever, muscle aches, vomiting and bleeding. In the current EBOV outbreak, at least 1,500 people have died as of the end of August. Two U.S. aid workers infected in that outbreak received an experimental treatment called ZMapp, a combination of three different monoclonal antibodies that bind to the protein of the virus. The newly described SUDV treatment also uses monoclonal antibodies, in this case synthetic antibodies designed to target a key molecule on the surface of SUDV called the envelope glycoprotein. (A glycoprotein molecule consists of carbohydrates plus a protein).
"While our antibodies show promise for treatment of SUDV infection, they wouldn't work against the EBOV outbreak now underway in West Africa," said Jonathan Lai, Ph.D., associate professor of biochemistry at Einstein and co-corresponding author of the ACS Chemical Biology paper. "That's because antibodies that kill off one strain, or species, of Ebola haven't proven effective against other strains."
In developing their SUDV therapy, the researchers started with specific antibodies made by mice. These antibodies protect the animals against SUDV infection by binding to the envelope glycoprotein on the surface of the virus. But if used in humans, mouse antibodies could provoke an immune response that would destroy them. Needing a "humanized" version of their mouse antibody, the researchers realized that its molecular structure closely resembled the structure of a commonly used human antibody.
The researchers used that human antibody as a scaffold onto which they placed the Ebola-specific portion of the mouse antibody. They then made variants of the resulting molecule by subtly changing its structure in different ways using a process called "synthetic antibody engineering." Two of these variants proved able to fend off SUDV in specially bred mice. "These two monoclonal antibodies represent potential candidates for treating SUDV infection," said Dr. Lai. He noted that more research is needed before the antibody therapy can be tested on humans.
The above post is reprinted from materials provided by Albert Einstein College of Medicine of Yeshiva University. Note: Content may be edited for style and length.
Cite This Page: